Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives

Source
EJHaem - ISSN 2688-6146-5:5 (2024) p. 1096-1099
Author(s)
    Bert Heyrman, Stef Meers, Selim Sid, Natalie Put, Koen Theunissen, Koen Van Eygen, Nathan De Beule, Maxime Clauwaert, Helena Maes, Alexander Salembier, Jan Lemmens, Ann Van de Velde, Dominik Selleslag, Jason Bouziotis, Ann De Becker, Sébastien Anguille

Designing and combining chimeric antigen receptors for improved cellular immunotherapy of hematological malignancies

Source
Antwerp, University of Antwerp, Faculty of Medicine and Health Sciences, 2024,239 p.
Author(s)

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study

Source
PLoS ONE - ISSN 1932-6203-19:7 (2024) p. 1-15
Author(s)

Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma : protocol of a monocentric phase I/II clinical trial in Belgium

Source
BMJ open - ISSN 2044-6055-14:3 (2024) p. 1-10
Author(s)